Eli Lilly and Company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of...
CREDIT: Dan Addison | University of Virginia Communications UVA Health researchers have discovered a molecule in the brain responsible for orchestrating the immune system’s responses to Alzheimer’s disease and multiple sclerosis (MS), potentially allowing doctors to...
The pursuit of a cure for Alzheimer’s disease is becoming an increasingly competitive and contentious quest with recent years witnessing several important controversies. In July 2022, Science magazine reported that a key 2006 research paper, published in the...
